HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice.

Abstract
The role of spinal cannabinoid systems in neuropathic pain of streptozotocin (STZ)-induced diabetic mice was studied. In normal mice, injection of the cannabinoid receptor agonist WIN-55,212-2 (1 and 3μg, i.t.) dose-dependently prolonged the tail-flick latency, whereas there were no changes with the injection of either cannabinoid CB1 (AM 251, 1 μg, i.t.) or CB2 (AM 630, 4 μg, i.t.) receptor antagonists. AM 251 (1 μg, i.t.), but not AM 630 (4 μg, i.t.), significantly inhibited the prolongation of the tail-flick latency induced by WIN-55,212-2 (3 μg, i.t.). In STZ-induced diabetic mice, the tail-flick latency was significantly shorter than that in normal mice. A low dose of WIN-55,212-2 (1 μg, i.t.) significantly recovered the tail-flick latency in STZ-induced diabetic mice. The effect of WIN-55,212-2 (1 μg, i.t.) in STZ-induced diabetic mice was significantly inhibited by AM 630 (4 μg, i.t.), but not AM 251 (1 μg). The selective cannabinoid CB2 receptor agonist L-759,656 (19 and 38 μg, i.t.) also dose-dependently recovered the tail-flick latency in STZ-induced diabetic mice, and this recovery was inhibited by AM 630 (4 μg, i.t.). The protein levels of cannabinoid CB1 receptors, CB2 receptors and diacylglycerol lipase α (DGL-α), the enzyme that synthesizes endocannabinoid 2-arachidonoylglycerol, in the spinal cord were examined using Western blotting. The protein levels of both cannabinoid CB1 and CB2 receptors were increased in STZ-induced diabetic mice, whereas the protein level of DGL-α was significantly decreased. These results indicate that spinal cannabinoid systems are changed in diabetic mice and suggest that cannabinoid CB2 receptor agonists might have an ability to recover diabetic neuropathic pain.
AuthorsH Ikeda, M Ikegami, M Kai, M Ohsawa, J Kamei
JournalNeuroscience (Neuroscience) Vol. 250 Pg. 446-54 (Oct 10 2013) ISSN: 1873-7544 [Electronic] United States
PMID23892011 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Arachidonic Acids
  • Benzoxazines
  • Chromans
  • Endocannabinoids
  • Glycerides
  • L 759656
  • Morpholines
  • Naphthalenes
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • glyceryl 2-arachidonate
  • Lipoprotein Lipase
Topics
  • Animals
  • Arachidonic Acids (biosynthesis)
  • Benzoxazines (pharmacology)
  • Blotting, Western
  • Chromans (pharmacology)
  • Diabetes Mellitus, Experimental (complications)
  • Endocannabinoids (biosynthesis)
  • Glycerides (biosynthesis)
  • Injections, Spinal
  • Lipoprotein Lipase (metabolism)
  • Male
  • Mice
  • Mice, Inbred ICR
  • Morpholines (pharmacology)
  • Naphthalenes (pharmacology)
  • Neuralgia (drug therapy, etiology)
  • Pain Measurement (drug effects)
  • Pain Threshold (drug effects)
  • Reaction Time (drug effects)
  • Receptor, Cannabinoid, CB1 (metabolism)
  • Receptor, Cannabinoid, CB2 (agonists, metabolism)
  • Spinal Cord (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: